You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
益方生物(688382.SH):計劃在今年ESMO上披露更多MRCT臨牀研究數據
格隆匯 07-24 09:02

格隆匯7月24日丨益方生物(688382.SH)近期在接待機構投資者調研時表示,公司KRAS G12C抑制劑D-1553國內已經完成臨牀Ia和Ib期試驗,並已於去年6月左右啟動了在非小細胞肺癌單臂二期註冊臨牀試驗,目前正常進展中。同時,在國際多中心(MRCT)也正在進行在肺癌一線和其他實體瘤適應症的單藥與聯合用藥的臨牀I/II期研究。公司在今年ASCO會議上披露了D-1553在結直腸癌(CRC)單藥的早期臨牀數據。公司也計劃在今年ESMO上披露更多MRCT臨牀研究數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account